
PUMA BIOTECHNOLOGY, INC. — Investor Relations & Filings
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. The company's primary commercial product is Nerlynx® (neratinib), an FDA-approved oral medication for certain types of breast cancer. Its clinical pipeline includes alisertib, an investigational drug being evaluated in clinical trials for small cell lung cancer and metastatic breast cancer. The company's mission is to develop and commercialize innovative products to enhance cancer care.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-05-07 | English | |
| ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-04-28 | English | |
| SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject) | 2026-03-27 | English | |
| 10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | |
| 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | |
| 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 43531573 | 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-05-07 | English | ||
| 38160772 | ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-04-28 | English | ||
| 33062747 | SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject) | 2026-03-27 | English | ||
| 32891304 | 10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | ||
| 32891296 | 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | ||
| 32700165 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 32700155 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 32700152 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 29414787 | 4 Filing | 2026-01-08 | English | ||
| 29414786 | 4 Filing | 2026-01-08 | English | ||
| 29414770 | 4 Filing | 2026-01-08 | English | ||
|
2025
4 filings
| |||||
| 12162691 | FORM 4 | 2025-11-13 | English | ||
| 12162694 | Regulatory Filings 2025 | 2025-11-12 | English | ||
| 12162697 | FORM 10-Q | 2025-11-06 | English | ||
| 12162702 | FORM 8-K | 2025-11-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Biocon Ltd.
Develops biosimilars and novel biologics for diabetes, onco…
|
BIOCON | IN | Manufacturing |
|
BIOCRYST PHARMACEUTICALS INC
Develops novel medicines for patients with rare and serious…
|
BCRX | US | Manufacturing |
|
Biocure Technology Inc.
Develops and commercializes advanced biological medicines, …
|
CURE.X | CA | Manufacturing |
|
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Develops novel antibody-based drugs and provides integrated…
|
2315 | HK | Manufacturing |
|
Biodexa Pharmaceuticals Plc
Clinical-stage biopharma developing treatments for rare dis…
|
BDRX | GB | Manufacturing |
|
BioDlink International Company Limited
Integrated biopharmaceutical CDMO specializing in ADC platf…
|
1875 | HK | Manufacturing |
|
BioEnvelop Technologies Corporation
Developed rapidly dissolving edible film strips for nutrace…
|
BIE | CA | Manufacturing |
|
Biofarm S.A.
A pharmaceutical company that manufactures and markets medi…
|
BIO | RO | Manufacturing |
|
BIO-FD&C CO.,LTD.
Develops active ingredients for cosmetics and pharma using …
|
251120 | KR | Manufacturing |
|
Biofil Chemicals & Pharmaceuticals
Produces pharmaceutical formulations, bulk drugs, and plast…
|
BIOFILCHEM | IN | Manufacturing |
PUMA BIOTECHNOLOGY, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33488/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33488 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33488 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33488 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33488}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PUMA BIOTECHNOLOGY, INC. (id: 33488)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.